ArticleCureus2025
Metabolic Dysfunction-Associated Steatohepatitis With Positive Antimitochondrial M2 Antibodies: Diagnostic Pitfall and Importance of Follow-Up.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic dysfunction-associated steatohepatitis (MASH) is a subtype of metabolic dysfunction-associated steatotic liver disease (MASLD) characterized by liver fat accumulation and inflammation. Occasionally, patients with MASH may test positive for antimitochondrial M2 antibodies (AMA-M2), which are usually linked to primary biliary cholangitis (PBC), creating potential diagnostic confusion. We report the case of a 52-year-old woman with obesity and persistent liver enzyme elevation, who was found to have positive AMA-M2 antibodies. Imaging revealed moderate hepatic steatosis, and liver biopsy confirmed MASH without evidence of PBC. After adopting lifestyle modifications, the patient achieved significant weight loss and normalization of liver and lipid profiles. At the one-year follow-up, the patient showed isolated elevation of alkaline phosphatase, which, together with positive anti-M2 antibodies, led to a diagnosis of PBC and initiation of ursodeoxycholic acid therapy. This case illustrates that anti-M2 antibodies may be found in patients with MASH alone or in those with MASH associated with PBC, highlighting the importance of careful evaluation and long-term follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.